New wearable capnograph could revolutionize ambulance monitoring
NCT ID NCT06905613
First seen May 08, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This study tested a new wearable capnograph called MARIE in an ambulance setting. The device measures exhaled carbon dioxide and breathing rate. 20 healthy volunteers and 30 patients being transported by ambulance participated. The goal was to see if the device gives reliable readings during transport.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMBULANCES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ambulansstationen Uppsala Region
Uppsala, Uppsala County, 75185, Sweden
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Wearable capnograph (MARIE) device
What this could lead to
If successful, this could lead to better monitoring of patients during ambulance transport, potentially enabling earlier treatment.
What could go wrong
This is a small, early feasibility study with only 49 participants. The device may not work reliably in real-world conditions, and results may not apply to all patients.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.